Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression

The PIKTAM study evaluated the efficacy and safety of the PI3K inhibitor buparlisib in combination with tamoxifen in hormone receptor‐positive (HR(+)), HER2‐negative advanced breast cancer patients after failure of prior endocrine therapy. In this open‐label, single‐arm phase II trial, 25 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Welt, Anja, Wiesweg, Marcel, Theurer, Sarah, Abenhardt, Wolfgang, Groschek, Matthias, Müller, Lothar, Schröder, Jan, Tewes, Mitra, Chiabudini, Marco, Potthoff, Karin, Bankfalvi, Agnes, Marschner, Norbert, Schuler, Martin, Breitenbücher, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333856/
https://www.ncbi.nlm.nih.gov/pubmed/32352244
http://dx.doi.org/10.1002/cam4.3092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333856/
https://www.ncbi.nlm.nih.gov/pubmed/32352244
http://dx.doi.org/10.1002/cam4.3092

Ejemplares similares